 | | Vol. 2.01 – 14 January, 2021 |
| |
|
|
| Scientists used human tonsils, readily available lymphoid organs, to develop a functional organotypic system that recapitulated key germinal center features in vitro, including the production of antigen-specific antibodies, somatic hypermutation and affinity maturation, plasmablast differentiation and class-switch recombination.
[Nature Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors showed that concomitant mutation of Apc and Kras in the mouse intestinal epithelium profoundly rewires metabolism, increasing glutamine consumption.
[Nature Genetics] |
|
|
|
| Researchers established a novel intestinal organoid culture system composed of eight components, mainly including VPA, EPZ6438, LDN193189, and R-Spondin 1 conditioned medium, which mimicked the gut epithelium regeneration that produced hyperplastic crypts following injury.
[Cell Research] |
|
|
|
| Intestinal organoids were grown from rectal biopsies in a cohort of 97 subjects with cystic fibrosis. Residual CFTR function was measured by quantifying organoid swelling induced by forskolin and response to modulators by quantifying organoid swelling induced by CFTR correctors, potentiator and their combination. Organoid data were correlated with clinical data from literature.
[European Respiratory Journal] |
|
|
|
| Investigators took advantage of induced pluripotent stem cells to develop an induced human ulcerative colitis-derived organoid model and compared it with the induced human normal organoid model.
[Nature Communications] |
|
|
|
| Scientists report that CREPT, a recently identified tumor-promoting protein, was required for the maintenance of murine intestinal stem cells. CREPT was preferably expressed in the crypts but not in the villi.
[Nature Communications] |
|
|
|
| Researchers used three independent approaches to probe the capacity of SARS-CoV-2 to infect the brain. Using human brain organoids, they observed clear evidence of infection with accompanying metabolic changes in infected and neighboring neurons.
[Journal of Experimental Medicine] |
|
|
|
| Combining biochemical methods, 3D organoid cultures and in vivo approaches, scientists demonstrated that intestinal H3 clipping was the result of multiple proteolytic activities.
[Nucleic Acids Research] |
|
|
|
| Investigators describe a protocol for the continuous patterning of hepatic, biliary and pancreatic structures from a 3D culture of human pluripotent stem cells.
[Nature Protocols] |
|
|
|
| Researchers used CRISPR/Cas9 gene editing to engineer an NRL-deficient embryonic stem cell line, and differentiated it into retinal organoids.
[Stem Cells] |
|
|
|
| The authors present an innovative ultra-high-content assay platform for interrogating T-cell-mediated killing of 3D multicellular tumor spheroids.
[Communications Biology] |
|
|
|
| Scientists employed RNA-sequencing to asses transcriptomic response to ethanol exposure in 3D organoid lines derived from healthy colon. Paired regression analysis identified 2,162 differentially expressed genes in response to ethanol.
[Scientific Reports] |
|
|
|
| Investigators present a step-by-step methodology to generate human minibrain nurseries and novel strategies to subsequently label projection neurons, perform immunohistochemistry and 3D imaging of the minibrains at large multiplexable scales.
[Frontiers in Bioengineering and Biotechnology] |
|
|
|
|
| The authors discuss ex vivo experimental models available to study the effect of COVID-19 on tissue stem cells.
[Cells] |
|
|
|
|
| BlueRock Therapeutics, in collaboration with Memorial Sloan Kettering Cancer Center, announced that the US FDA has cleared their Investigational New Drug application to proceed with a Phase I study in patients with advanced Parkinson’s disease (PD). This is the first trial in the US to study pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson’s disease.
[BlueRock Therapeutics (PR Newswire, Inc.)] |
|
|
|
| The Seaver Autism Center for Research and Treatment at the Icahn School of Medicine at Mount Sinai and Rumi Scientific announced today that they will team up to initiate a drug discovery pipeline for rare genetic disorders that carry a high risk of autism. The project will initially involve the development and use of a platform that mimics the development of brain tissues, at high speed, allowing researchers to gain insights into how cells respond to three known genes implicated in autism.
[Mount Sinai Health System] |
|
|
|
|
| February 3 – 23, 2021
Virtual |
|
|
|
|
|
| | University of Luxembourg – Belval, Luxembourg |
|
|
|
| | Cedars-Sinai – Los Angeles, California, United States |
|
|
|
| | National Institute of Arthritis and Musculoskeletal and Skin Diseases – Washington, DC, United States |
|
|
|
| | Lieber Institute for Brain Development – Baltimore, Maryland, United States |
|
|
|
| | Genentech, Inc. – South San Francisco, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
